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1879 by the great German scientist Paul Ehrlich and during
the following 20–30 years attracted tremendous interest by
biomedical scientists. During these years it was discovered
that increased numbers of eosinophils in blood were
frequent findings in patients suffering from parasite or
helminth diseases, but also by those suffering from allergic
diseases, in particular bronchial asthma. The conclusions
about the biological role of the eosinophil drawn from these
early findings was that this cell acts as a protective cell
against invading parasites and also that the cell probably
counteracted many of the adverse reactions taking place in
allergic disease. Although part of these conclusions have
been modified during recent years the actual role of the
eosinophil in health and disease remains enigmatic in spite
of the huge progress that has been made during the last few
decades in the understanding of the biochemistry and
functions of this cell in vitro. Thus, the assumption about a
role of the eosinophil in parasite and helminth defence
reactions is still valid and has been strengthened by
several findings related to in-vitro findings of the capacity
of products secreted by the activated eosinophil to actually
damage and kill such organisms. However, recent findings
seem to broaden the role of the eosinophil in host
defence reactions, since such products also kill bacteria
and viruses.
The cytotoxic capacity of the eosinophil is attributed to
the secretion of several basic proteins from the cell, but also
from the fact that the eosinophil is a very potent producer
of toxic and reactive oxygen species. Thus, the cytotoxic
potential of the eosinophil is quite impressive and it is not
surprising that damage to host cells may occur if the cell is
activated inappropriately. The consequence of eosinophil
cytotoxicity may be the epithelial damage seen in several
diseases such as bronchial asthma and other allergic
diseases or ulcerative colitis and the consequences in these
diseases are obviously harmful to the host. However, the
cytotoxic capacity may also be turned against cancer
tumours and may, in those cases, be beneficial to the host.
Other diseases in which the cytotoxic activity may play a
pathogenetic role are lung diseases such as respiratory
distress syndrome (RDS), chronic obstructive pulmonary
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any cell in the body if present in suciently high numbers.
The most dramatic proof of the potential harmfulness of
the eosinophil is the hyper-eosinophilic syndrome, since all
clinical problems encountered by these subjects are
probably explained by the mere presence of the huge
number of eosinophils in blood and tissues.
Although the cytotoxic potential of the eosinophil is the
most conspicuous, other activities have been attributed to
this cell that may be of equal importance. One of these is
the potential role of eosinophils in tissue repair processes
and in processes of excess fibrosis in diseases such as
pulmonary fibrosis. Thus, it has been clearly demonstrated
that eosinophils are invariably present in processes where
tissue repair is taking place and also in prominent cells in
tissues of excessive fibrosis. In addition, recent findings
indicate that eosinophil products affect fibroblasts and their
production of collagens and proteoglycans. One of the
important questions, therefore, to answer is whether these
activities are involved in the structural changes seen in
bronchial asthma, since it is assumed that these structural
changes or tissue remodellings are the underlying mechan-
isms of the chronicity of this disease. Further, it is quite
clear that the eosinophil has the potential of being an
immunomodulatory cell with a remarkable capacity of
producing a whole range of potent cytokines. It has even
been suggested that eosinophils may adopt a Th1- and Th2-
like phenotype, with either preferential production of Th1
cytokines or with the production of Th2 cytokines. Such
results emphasize a long-standing assumption, which gains
more and more support, that the eosinophils may
dramatically change phenotype and activities depending
on the environment and circumstances under which
they are operating—a phenomenon often referred to as
priming.
The activation and priming of eosinophils are dependent
on the presence of receptors on the surface of the cell and,
not unexpectedly, numerous such receptors have been
identified, which are important for the recognition of prey,
such as immunoglobulin and complement receptors,
chemokine receptors for the regulation of cell migration,
and cytokine and growth factor receptors for the regulation
of growth and priming. The eosinophil is a bone marrow-
derived cell originating from the myeloid precursor cells
and the growth factors regulating the expansion of
eosinophil precursors are partly common to other myeloid
cells, whereas the commitment into eosinophils seems to be
mainly governed by interleukin-5 (IL-5). In the human# 2001 HARCOURT PUBLISHERS LTD
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growth and activation of eosinophils, since IL-5 is also
operative in activation and priming of mature eosinophils.
Therefore the clinical trials in asthmatic subjects with anti-
IL-5 antibodies were met with great expectations and
excitement and the greater was the disappointment when it
was found that the antibodies indeed reduced the number
of circulating eosinophils and eosinophils in sputum,
without affecting significantly the development of the
occurrence of the late asthmatic reaction after allergen
challenge. These results have told us two things. First of all
that IL-5 is important for the growth and development of
eosinophils in humans, but also that the impact of
eosinophils on the disease process of asthma is not simple
and that these cells may not be involved to any greater
extent in the development of the late asthmatic reaction. So
what is the role of eosinophils in asthma? Are they mere
bystanders in the process or do they have a role in thedevelopment of chronic asthma as alluded to above.
However, most importantly of all the results from the
anti-IL-5 antibody studies demonstrate to all of us that the
enigma of the eosinophil persists and that much more
research into this fascinating but mysterious cell is needed.
It is therefore timely that an International Eosinophil
Society (www.eosinophil-society.org) has been formed to
promote and stimulate research and knowledge of this cell.
Two events are of major importance in this regard. One is
the arrangements of conferences every second year on
eosinophil research, with the next meeting occuring in
Banff, Canada, May 4–8, 2001. The second is the invitation
by Respiratory Medicine to me to take editorial responsi-
bility for a section on Eosinophils and Respiratory Disease in
the Journal. I have accepted this invitation with great
expectations and excitement and hereby invite any paper on
eosinophils in health and disease to be submitted for
consideration.
